|
KMID : 0354619960080010001
|
|
Journal Dankook Dental Research Institute
1996 Volume.8 No. 1 p.1 ~ p.10
|
|
|
Clinical Study of Malignant Salivary Gland Tumors
|
|
|
|
|
Abstract
|
|
|
Malignant tumors of the salivary glands account for a relatively small number(4%) of head and neck tumors, but generate considerable interest because of their remarkable variation in clinical presentation, histologic appearance, and behaviors.
Successful treatment of these lesions is a major challenge because of the disposition these tumors to recur locally as well al distantly. In my study, 46 cases treated from 1982 to 1995 at Korea cancer center hospital are analyzed retrospectively
&
clinically.
@EN The obtained results were as followings.
@EN 1. The mean age of patients was 52.7 years old and male & female ratio was 6:4.
2. The common symptoms were mass(45.6%), pain(19.5%), ulcer(13%) and the duration of chief complaints almost was within 6 months.
3. According to histopathology, adenoid cystic carcinoma was most common (43%), and according to the criteria of the AICC on staging, stages were as followings : stage 1 10.8%, stage 2 23.9%, stage 3 26%, stage 4 39.1%.
4. In treatment modalities, modified triple modalities(chemotherapy + radiation therapy + surgery) was most common(28%), surgery alone was 21.7%, and surgery combined radiation therapy was 195%.
5. Among all 46 patients, there were 17%(37%) recurrences. Locoregional recurrence alone occured in 10 patients, distant metastasis alone in 11 patients, and locoregional recurrence with distant metastasis in 2 patients
6. Overall survival rates of entire group by Kaplan-Meier method was 50.1% at 5 years.
7. The 5 year survival rate was 77.1% in early staged patients, in contrast to 35.3% in advanced patients(P<0.05).
8. The 5 year survival rate for patients without cervical lymph node metastasis was 56.6%, in contrast to 36.9% for patients presented with nodal disease initially.
9. In 5 year survival rates according to histopathology, 46.6% in mucoepidermoid carcinoma, 49.2% in adenoid cystic carcinoma, 40% in adenocarcinoma & malignant mixed tumor & malignant myoepithelioma, 100% in terminal duct carcinoma were seen.
10. In 5 vear survival rates according to various modalities of treatment, 20% in untreated patients and 83.8% in surgery alone, 68.5% in surgery combined radiation therapy, 46.6% in modified triple modalities (chemotherapy + radiation therapy +
surgery) were seen(P<0.01).
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|